Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345
Farbotko S, Owen A, Orchard SG, Woods RL, Nelson M, Stocks NP, Tonkin A, Wolfe R, McNeil J, Gibbs P, Zalcberg J, Ryan J. Incidence of major health events across metropolitan and regional areas: A 10+ year prospective study of 16,697 older Australians. Australasian Journal on Ageing. 2025;44(2):10.1111/ajag.70036
McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125
Hecht JR, Elez E, Eng C, Gibbs P, Seligmann JF, Xu R-H, Yamaguchi K, Wang C-Y, Teng HW, Trani L, Wortman-Vayn H, Jiang Z, Diorio B, Lorenzini PA, Baudelet C, Sethi SN, Baig M, Cremolini C. OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.tps3638
Sanderson E, Gibbs P, Tie J. The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health – Western Pacific. 2025;59:10.1016/j.lanwpc.2025.101595
Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503
Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. 2025;31(5):10.1038/s41591-025-03579-w
Kim GY, Tie J, Gibbs P. Letter to the Editor: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?. Journal of the National Comprehensive Cancer Network. 2025;23(5):10.6004/jnccn.2025.7037
Gard G, Oakley J, Serena K, Harold M, Gray K, Anderson H, Byrne J, Cockwill J, Cormack J, Down G, Kiossoglou G, Gibbs P. Stronger together; evaluating consumers and researchers working in partnership. Research Involvement and Engagement. 2025;11(1):10.1186/s40900-025-00716-0
Besson A, Cao K, Mardinli A, Wirth L, Yeung J, Kokelaar R, Gibbs P, Reid F, Yeung JM. Artificial intelligence generated 3D body composition predicts dose modifications in patients undergoing neoadjuvant chemotherapy for rectal cancer. Journal of Cancer Research and Clinical Oncology. 2025;151(5):10.1007/s00432-025-06219-5